Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 5NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other neoplasm 1Gastrointestinal 1

Conditions

Precancerous Conditions 1Colorectal Neoplasms 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 109Bevacizumab 97Magnetic Resonance Spectroscopy 91Specimen Handling 88Biopsy 75Paclitaxel 64fludarabine phosphate 62Immunoglobulin G 61Disulfides 61Carboplatin 58Taxes 53Cisplatin 52Doxorubicin 51fludarabine 49Sorafenib 46Radiation 46aldesleukin 45Radiotherapy 45Prednisone 45Etoposide 45Vincristine 41Sirolimus 40Platinum 40Bortezomib 38Rituximab 371,2-diaminocyclohexaneplatinum II citrate 37Nivolumab 36Cytarabine 35temsirolimus 34Vorinostat 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Has results × Eflornithine × Clear all
NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT00983580 2019-09-04

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
107 enrolled 10 charts

Adenomatous Polyps

NCT00118365 2015-01-22

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

National Cancer Institute (NCI)

Phase 3 Completed
375 enrolled 27 charts
Other neoplasm

Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡